RYTM - RHYTHM PHARMACEUTICALS, INC.
IEX Last Trade
55.44
0.125 0.225%
Share volume: 7,001
Last Updated: Fri 27 Dec 2024 05:29:49 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$55.32
0.13
0.23%
Fundamental analysis
25%
Profitability
25%
Dept financing
12%
Liquidity
75%
Performance
15%
Performance
5 Days
-0.34%
1 Month
-9.85%
3 Months
9.23%
6 Months
40.08%
1 Year
16.23%
2 Year
91.01%
Key data
Stock price
$55.44
DAY RANGE
$54.83 - $56.18
52 WEEK RANGE
$36.01 - $68.58
52 WEEK CHANGE
$18.63
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: David P. Meeker
Region: US
Website: rhythmtx.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: rhythmtx.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Rhythm Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency.
Recent news